X0508 4 2025-12-01 0 0001576280 Guardant Health, Inc. GH 0001652956 Monroe Terilyn J. 3100 HANOVER STREET PALO ALTO CA 94304 0 1 0 0 Chief People Officer 1 Common Stock 2025-12-01 4 M 0 35000 20.14 A 61087 D Common Stock 2025-12-01 4 M 0 15000 28.61 A 76087 D Common Stock 2025-12-01 4 S 0 18576 105.33 D 57511 D Common Stock 2025-12-01 4 S 0 23974 106.15 D 33537 D Common Stock 2025-12-01 4 S 0 6786 106.90 D 26751 D Common Stock 2025-12-01 4 S 0 664 107.85 D 26087 D Common Stock 2025-12-01 4 S 0 1923 105.33 D 24164 D Common Stock 2025-12-01 4 S 0 2444 106.18 D 21720 D Common Stock 2025-12-01 4 S 0 800 107.03 D 20920 D Stock Option (Right to Buy) 20.14 2025-12-01 4 M 0 35000 0 D 2034-02-26 Common Stock 35000 43204 D Stock Option (Right to Buy) 28.61 2025-12-01 4 M 0 15000 0 D 2034-11-08 Common Stock 15000 32627 D Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.625 to $105.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.625 to $106.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.625 to $107.560. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.730 to $107.970. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.680 to $105.620. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.680 to $106.670. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.710 to $107.770. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. This represents a stock option granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025, and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter. /s/ John G. Saia, as attorney-in-fact for Tarilyn J. Monroe 2025-12-02